Claims
- 1. A pharmacological composition, comprising:
a chelator in a time release formulation in a quantity sufficient to reduce a serum concentration of a bivalent metal in an amount of at least 20% for a period of at least 8 hrs.
- 2. The composition of claim 1 wherein the chelator is in a quantity sufficient to reduce a serum concentration of a bivalent metal in an amount of at least 30% for a period of at least 10 hrs.
- 3. The composition of claim 1 wherein the chelator is in a quantity sufficient to reduce a serum concentration of a bivalent metal in an amount of at least 40% for a period of at least 12 hrs.
- 4. The composition of claim 1 wherein the chelator chelates at least one of Ca2+ and Mg2+.
- 5. The composition of claim 4 wherein the chelator is selected from the group consisting of 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid, Ethylenebis(oxyethylenenitrilo)tetraacetic acid, 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester), trans-1,2-diaminocyclohexane-tetraacetic acid, and diethyllenetriamine-pentaacetic acid.
- 6. The composition of claim 4 wherein the chelator is selected from the group consisting of tri-methylaminetricarboxylic acid, poly(aspartic acid), and poly(glutamic acid).
- 7. The composition of claim 4 wherein the chelator is ethylenediamine-N,N,N′,N′-tetraacetic acid.
- 8. The composition of claim 1 wherein the bivalent metal is at least one of Ca2+ and Mg2+.
- 9. The composition of claim 1 further comprising an antiviral agent.
- 10. The composition of claim 9 wherein the antiviral agent is selected from the group consisting of a cytokine, an antibody, Zn2+, a reverse transcriptase inhibitor, a protease inhibitor, and an antibody.
- 11. The composition of claim 1 wherein the composition reduces a viral serum titer of a virus in an amount of at least 10% for a period of at least 4 hours.
- 12. The composition of claim 1 wherein the composition reduces a viral serum titer of a virus in an amount of at least 25% for a period of at least 6 hours.
- 13. The composition of claim 1 wherein the composition reduces a viral serum titer of a virus in an amount of at least 40% for a period of at least 8 hours.
- 14. The composition of claim 10 wherein the virus is a retrovirus.
- 15. The composition of claim 14 wherein the retrovirus is an HIV virus or an HCV virus.
Parent Case Info
[0001] This application claims the benefit of U.S. provisional application No. 60/294,478 filed May 30, 2001, incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60294478 |
May 2001 |
US |